

2026 Independent Medical Education Request for Proposals

Issue Date: June 12, 2026

The *Independent Medical Education team at Genentech, a member of the Roche Group*, invites accredited educational providers to submit applications for independent, certified medical education grants subject to the terms described below. This Request for Proposals (RFP) provides public notice of the availability of funds in a general topic area for activities for which recognized scientific or educational needs exist and funding is available.

Purpose: As part of Genentech’s scientific mission, Genentech supports grants for independent medical education that aim to improve patient care by focusing on the improved application of knowledge, competence, and performance among healthcare professionals. This mission is achieved by supporting quality independent education that addresses evidence-based, bona fide educational gaps in accordance with the ACCME, AMA, PhRMA Code, OIG and FDA guidance.

Notification: Genentech RFPs are made available through our online Genentech Funding Request System (gFRS) site (funding.gene.com) along with the websites for the Alliance for Continuing Education in the Health Professions (ACEhp). In addition, an email is distributed to all registered gFRS users who have previously applied for support of an independent education activity. The email distribution list may not always be up to date. Please periodically check our online Genentech Funding Request System (gFRS) site (funding.gene.com) to stay informed on current funding priorities. *There have been no predetermined approvals, nor any identified preferred educational providers. All submissions will be reviewed equally and thoroughly.*

Terms and Conditions

1. All grant applications received in response to this RFP will be reviewed in accordance with all Genentech policies and policy guidelines. (Please refer to the publicly available criteria on funding.gene.com)
2. This RFP does not commit Genentech to award a grant or pay any costs incurred in the preparation of a response to this request.
3. Genentech reserves the right to approve or deny any or all applications received as a result of this request or to cancel, in part or in its entirety, this RFP.
4. For compliance reasons, and in fairness to all providers, all communications about this RFP must come exclusively to Genentech’s department of Medical Education and Research Grants. Failure to comply will automatically disqualify providers.
5. Failure to follow the instructions within this RFP may result in a denial.

Instructions

Eligibility Criteria	<ul style="list-style-type: none"> ● U.S. based education provider ● Registered account in gFRS ● Accredited to provide CME/CE and in good standing (e.g. ACCME, ANCC, ACPE, etc.)
Geographical Scope	<ul style="list-style-type: none"> ● Educational initiatives must be U.S.-based only

Submission Directions	Application Process	Milestones
Step 1	Providers who meet the eligibility criteria and are interested in submitting a response to this RFP will have 4 weeks to complete a full grant proposal through funding.gene.com . When submitting the application, please be sure to: <ul style="list-style-type: none"> • Select the Therapeutic Area (Neuroscience), and Disease State (Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease) • Include “MOGAD RFP June 2026 [Insert Your Program Title]” in the program title of the grant 	Please submit by July 24, 2026
Step 2	Grant decisions will be made by Genentech and decision notifications will be issued to the accredited educational provider through gFRS.	July 2025 through September 2025

Additional Considerations

Provider(s) who are awarded grants are encouraged but not required to:

1. Demonstrate key findings via outcomes analysis and report the extent to which the education met the stated objectives and other key findings.
2. Describe how learners demonstrated competence, performance, or improved patient outcomes as a result of the educational activity.
3. Summarize (through written analysis) the provider’s understanding and interpretation of the outcomes data and identify any persistent educational gaps, unanticipated barriers and/or activity/outcomes limitations.

Currently Available RFP Focus Area:

Focus	Opportunity
<p>Therapeutic Area: Neurology</p> <p>Disease Areas: Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)</p> <p>Primary Learning Audiences: Neuroimmunologists</p> <p>General Neurologists</p> <p>Emergency Medicine Physicians</p> <p>Primary Care Providers</p> <p>Ophthalmologists</p> <p>Support Available: Up to \$200,000</p>	<p>Although the 2023 International MOGAD Panel diagnostic criteria established formal standards for identifying myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), many community neurologists and general practitioners still struggle to differentiate MOGAD from overlapping demyelinating conditions, such as multiple sclerosis (MS) and aquaporin-4 (AQP4)-positive neuromyelitis optica spectrum disorder (NMOSD).</p> <p>This diagnostic ambiguity is exacerbated by a lack of familiarity with proper testing protocols and a low awareness of how to interpret low-positive antibody titers in the context of core clinical phenotypes like optic neuritis, transverse myelitis, and acute disseminated encephalomyelitis (ADEM). Consequently, a knowledge gap persists around referral best practices, with delayed or deferred escalations to neuroimmunology specialists which can lead to misdiagnosis, inappropriate treatment selection, and long-term neurological disability.</p> <p>The management of MOGAD has been traditionally reliant on repurposed, off-label immunosuppressants, but is currently undergoing a shift with the emergence of targeted, disease-specific mechanisms. As management of MOGAD shifts, busy healthcare providers face increasing difficulty in staying current on emerging treatment options.</p> <p>Genentech is seeking to support education that addresses clinical education gaps for MOGAD diagnosis and management to optimize evidence-based patient care.</p> <p>References:</p> <ol style="list-style-type: none"> Banwell, B., et al. (2023). Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. <i>The Lancet. Neurology</i>, 22(3), 268–282. https://doi.org/10.1016/S1474-4422(22)00431-8 Santoro, J. D., Gould, J., Panahloo, Z., Thompson, E., Lefelar, J., & Palace, J. (2023). Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients. <i>Neurology and therapy</i>, 12(4), 1081–1101. https://doi.org/10.1007/s40120-023-00474-9 Sechi, E., Cacciaguerra, L., Chen, J. J., Mariotto, S., Fadda, G., Dinoto, A., Lopez-Chiriboga, A. S., Pittock, S. J., & Flanagan, E. P. (2022). Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. <i>Frontiers in neurology</i>, 13, 885218. https://doi.org/10.3389/fneur.2022.885218